Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach